JAT 4.17% 34.5¢ jatcorp limited

Even though lactoferrin is widely recognised as an inflammatory...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 725 Posts.
    lightbulb Created with Sketch. 105
    Even though lactoferrin is widely recognised as an inflammatory modulator, I don't think that a small cap co would take the risk to say it is ok for people with lactose intolerance or any other Inflammatory gastrointestinal diseases. I would prefer that Sunnya/ JAT left it to individuals to work out if it is good for their children and to communicate the beneifts to others. Gastrointestinal problems seem too risky to me. They are often misdiagnosed and problems associated with them are hard to characterise accurately. Also there are a range of levels of severity. A slight improvement may not be viewed favourably by consumers. Increased immunity is a safe target to me and is attractive to a wide audience. In my view it is too risky for a company to make specific claims about lactose intolerance in marketing without testing a specific product in trials . Maybe down the track they could look into it or list some of the benefits that research has identified on their website to increase consumer awareness and so they can consider such benefits as a possibility. 
    Last edited by Jar-JarBinks: 03/03/19
 
watchlist Created with Sketch. Add JAT (ASX) to my watchlist
(20min delay)
Last
34.5¢
Change
-0.015(4.17%)
Mkt cap ! $58.28M
Open High Low Value Volume
36.5¢ 36.5¢ 34.5¢ $13.27K 36.83K

Buyers (Bids)

No. Vol. Price($)
3 8948 34.0¢
 

Sellers (Offers)

Price($) Vol. No.
35.0¢ 9426 1
View Market Depth
Last trade - 14.36pm 29/11/2024 (20 minute delay) ?
JAT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.